{"id":65231,"date":"2025-03-04T00:01:21","date_gmt":"2025-03-04T00:01:21","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2025\/03\/04\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/"},"modified":"2025-03-04T00:01:21","modified_gmt":"2025-03-04T00:01:21","slug":"investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/","title":{"rendered":"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum"},"content":{"rendered":"<div>\n<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1920208\/Telix_Main_Logo_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">MELBOURNE, Australia<\/span> and <span class=\"xn-location\">INDIANAPOLIS, Ind.<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">March 4, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company&#8217;s late-stage and next-generation radiotherapeutic candidates in urologic oncology.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<\/p><\/div>\n<p>In this education session, Telix and global key opinion leaders will provide an overview on the development of its therapeutic candidates in prostate and kidney cancers:<\/p>\n<ul type=\"disc\">\n<li><span class=\"xn-person\">Neeraj Agarwal<\/span>, MD, Professor of Medicine and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute in <span class=\"xn-location\">Salt Lake City, UT<\/span>, will discuss the ProstACT Global Phase 3 trial of TLX591 (<sup>177<\/sup>Lu rosopatamab tetraxetan), Telix&#8217;s lead radio antibody-drug conjugate (rADC) therapy candidate in prostate cancer.<\/li>\n<li><span class=\"xn-person\">Eric Jonasch<\/span>, MD, Professor of Medicine in the Department of Genitourinary Medical Oncology at MD Anderson Cancer Center in <span class=\"xn-location\">Houston, TX<\/span>, will discuss the STARLITE studies of TLX250 (<sup>177<\/sup>Lu girentuximab) in combination with immunotherapy, in clear cell renal cell carcinoma.<\/li>\n<li><span class=\"xn-person\">Rodney Hicks<\/span>, MD, Professor of Medicine at the <span class=\"xn-org\">University of Melbourne<\/span> and Monash University; Founder, Chair, and Chief Medical Officer at the Melbourne Theranostic Innovation Centre in <span class=\"xn-location\">Australia<\/span>, will discuss TLX592 (<sup>64<\/sup>Cu\/<sup>225<\/sup>Ac RADmAb<sup>\u00ae<\/sup>) and the role of targeted alpha therapies in the treatment of prostate cancer.<\/li>\n<\/ul>\n<p><b>The webinar will be held on: <\/b><\/p>\n<p><b>EDT: <\/b><span class=\"xn-chron\">Tuesday March 11<\/span>, <span class=\"xn-chron\">5.30pm<\/span> \u00a0<br \/><b>AEDT<\/b>: <span class=\"xn-chron\">Wednesday March 12<\/span>, <span class=\"xn-chron\">8.30am<\/span><br \/>The event will run for approximately 1.5 hours.<\/p>\n<p>Participants can register for the webcast at the following link: <a href=\"https:\/\/edge.media-server.com\/mmc\/p\/39s4k7gw\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/edge.media-server.com\/mmc\/p\/39s4k7gw<\/a><\/p>\n<p><b>About <\/b><b>Telix Pharmaceuticals Limited <\/b><\/p>\n<p>Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in <span class=\"xn-location\">Melbourne, Australia<\/span>, with international operations in <span class=\"xn-location\">the United States<\/span>, <span class=\"xn-location\">Canada<\/span>, <span class=\"xn-location\">Europe<\/span> (<span class=\"xn-location\">Belgium<\/span> and <span class=\"xn-location\">Switzerland<\/span>), and <span class=\"xn-location\">Japan<\/span>. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). TLX591, TLX592 and TLX250 have not received a marketing authorization in any jurisdiction.<\/p>\n<p>Visit <a href=\"http:\/\/www.telixpharma.com\/\" target=\"_blank\" rel=\"nofollow\">www.telixpharma.com<\/a> for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on <a href=\"https:\/\/www.linkedin.com\/company\/telixpharma\/\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>,\u00a0<a href=\"https:\/\/x.com\/TelixPharma\" target=\"_blank\" rel=\"nofollow\">X<\/a>\u00a0and <a href=\"https:\/\/www.facebook.com\/TelixPharma\" target=\"_blank\" rel=\"nofollow\">Facebook<\/a>.<\/p>\n<p><b>Telix Investor Relations<\/b><\/p>\n<p>Ms. Kyahn Williamson<br \/>Telix Pharmaceuticals Limited<br \/>SVP Investor Relations and Corporate Communications<br \/>Email: <a href=\"mailto:kyahn.williamson@telixpharma.com\" target=\"_blank\" rel=\"nofollow\">kyahn.williamson@telixpharma.com<\/a>\u00a0<\/p>\n<p><i>This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. <\/i><\/p>\n<p class=\"prntac\">Legal Notices<\/p>\n<p><i>You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. <\/i><\/p>\n<p><i>The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including <span class=\"xn-location\">the United States<\/span>. The information and opinions contained in this announcement are subject to change without notification. \u00a0To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. <\/i><\/p>\n<p><i>This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as &#8220;may&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;plan&#8221;, &#8220;estimate&#8221;, &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;outlook&#8221;, &#8220;forecast&#8221; and &#8220;guidance&#8221;, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix&#8217;s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix&#8217;s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix&#8217;s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix&#8217;s preclinical and clinical trials, and Telix&#8217;s research and development programs; Telix&#8217;s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix&#8217;s product candidates, manufacturing activities and product marketing activities; Telix&#8217;s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix&#8217;s product candidates, if or when they have been approved; Telix&#8217;s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix&#8217;s expenses, future revenues and capital requirements; Telix&#8217;s financial performance; developments relating to Telix&#8217;s competitors and industry; and the pricing and reimbursement of Telix&#8217;s product candidates, if and after they have been approved. Telix&#8217;s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. <\/i><\/p>\n<p><i>\u00a92025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals\u00ae, <\/i><i>Telix <\/i><i>Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates \u2013 all rights reserved. Trademark registration status may vary from country to country.<\/i><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>MELBOURNE, Australia and INDIANAPOLIS, Ind., March 4, 2025 \/PRNewswire\/ &#8212; Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company&#8217;s late-stage and next-generation radiotherapeutic candidates in urologic oncology. In this education session, Telix and global key opinion leaders will provide an overview on the development of [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-65231","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum\" \/>\n<meta property=\"og:description\" content=\"MELBOURNE, Australia and INDIANAPOLIS, Ind., March 4, 2025 \/PRNewswire\/ &#8212; Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Compa\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-04T00:01:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/1920208\/Telix_Main_Logo_Logo.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum\",\"datePublished\":\"2025-03-04T00:01:21+00:00\",\"dateModified\":\"2025-03-04T00:01:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/\"},\"wordCount\":1006,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/\",\"name\":\"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2025-03-04T00:01:21+00:00\",\"dateModified\":\"2025-03-04T00:01:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/","og_locale":"en_US","og_type":"article","og_title":"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum","og_description":"MELBOURNE, Australia and INDIANAPOLIS, Ind., March 4, 2025 \/PRNewswire\/ &#8212; Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Compa","og_url":"https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2025-03-04T00:01:21+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/1920208\/Telix_Main_Logo_Logo.jpg?p=medium600"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum","datePublished":"2025-03-04T00:01:21+00:00","dateModified":"2025-03-04T00:01:21+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/"},"wordCount":1006,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/","url":"https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/","name":"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2025-03-04T00:01:21+00:00","dateModified":"2025-03-04T00:01:21+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/investor-webinar-telix-therapeutics-urology-showcase-and-expert-forum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/65231","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=65231"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/65231\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=65231"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=65231"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=65231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}